Intellia Therapeutics (NTLA) FCF Margin (2015 - 2026)
Intellia Therapeutics (NTLA) reported FCF Margin of 780.34% for Q1 2026, up 11587.0% year-over-year from N/an in Q1 2025, and down 159.11% on a QoQ basis from 301.16% in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of FCF Margin data on file, last reported at 780.34% in Q1 2026.
- Quarterly FCF Margin rose 11587.0% year-over-year to 780.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 549.51% (up 27408.0% YoY) and the FY2025 annual result came in at 583.36%, up 2043.0% from the prior year.
- FCF Margin slipped to 780.34% in Q1 2026 per NTLA's latest filing, from 301.16% in the prior quarter.
- Across five years, FCF Margin topped out at 4852.74% in Q4 2023 and bottomed at 976.87% in Q3 2024.
- The 5-year median for FCF Margin is 696.07% (2023), against an average of 369.56%.
- The widest annual swing landed in 2022, when FCF Margin surged 2256279 bps; it then slumped 548172 bps in 2024.
- Tracing NTLA's FCF Margin over 5 years: stood at 690.94% in 2022, then jumped by 802 bps to 4852.74% in 2023, then slumped by 113 bps to 628.98% in 2024, then jumped by 52 bps to 301.16% in 2025, then slumped by 159 bps to 780.34% in 2026.
- Per Business Quant, the three latest NTLA FCF Margin figures stand at 780.34% (Q1 2026), 301.16% (Q4 2025), and 557.97% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -780.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -780.34% |
| Dec 31, 2025 | -301.16% |
| Sep 30, 2025 | -557.97% |
| Jun 30, 2025 | -698.77% |
| Mar 31, 2025 | -896.20% |
| Dec 31, 2024 | -628.98% |
| Sep 30, 2024 | -976.87% |
| Jun 30, 2024 | -809.41% |
| Mar 31, 2024 | -425.67% |
| Dec 31, 2023 | 4,852.74% |
| Sep 30, 2023 | -790.53% |
| Jun 30, 2023 | -696.07% |
| Mar 31, 2023 | -897.67% |
| Dec 31, 2022 | -690.94% |
| Sep 30, 2022 | -623.87% |
| Jun 30, 2022 | -618.52% |
| Mar 31, 2022 | -742.29% |
| Dec 31, 2021 | -447.48% |
| Sep 30, 2021 | -23,186.67% |
| Jun 30, 2021 | -876.79% |
| Mar 31, 2021 | -826.64% |
| Dec 31, 2020 | -593.71% |
| Sep 30, 2020 | -138.19% |
| Jun 30, 2020 | 355.59% |
| Mar 31, 2020 | -787.80% |
| Dec 31, 2019 | -285.61% |
| Sep 30, 2019 | -271.32% |
| Jun 30, 2019 | -252.73% |
| Mar 31, 2019 | -209.90% |
| Dec 31, 2018 | -61.46% |
| Sep 30, 2018 | -213.32% |
| Jun 30, 2018 | -287.38% |
| Mar 31, 2018 | -262.69% |
| Dec 31, 2017 | -461.85% |
| Sep 30, 2017 | -164.84% |
| Jun 30, 2017 | -350.41% |
| Mar 31, 2017 | -189.48% |
| Dec 31, 2016 | -261.95% |
| Sep 30, 2016 | -168.72% |
| Jun 30, 2016 | 1,576.63% |
| Mar 31, 2016 | -581.82% |
| Dec 31, 2015 | -466.69% |
| Sep 30, 2015 | -136.73% |
| Jun 30, 2015 | 115.18% |
| Mar 31, 2015 | 334.84% |